Spotlight on multiple myeloma: New drug approvals highlight treatment advances

Myeloma Awareness Month is observed in March.

The campaign is intended to educate the public about the disease and the need for more effective treatments.

Hands holding burgundy ribbons. — *Source: Adobe Stock.*

In conjunction with this observance, Healio provides the following updates related to multiple myeloma research and therapy.

The FDA approved ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech), a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma. The indication applies to patients who received four or more previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. Read more.
The addition of daratumumab (Darzalex, Janssen) to pomalidomide (Pomalyst, Bristol Myers Squibb) and dexamethasone extended PFS among patients with relapsed or refractory multiple myeloma who were refractory to lenalidomide (Revlimid, Bristol Myers Squibb). Read more.
Researchers from Mount Sinai published a case study in Nature Medicine about a patient with multiple myeloma who developed neurocognitive and hypokinetic movement disorder with features of Parkinson’s disease after receiving ciltacabtagene autoleucel. Read more.
The addition of isatuximab (Sarclisa, Sanofi) to a standard three-drug induction regimen improved outcomes for patients with transplant-eligible, newly diagnosed multiple myeloma. Read more.
Although vaccination is an effective strategy for COVID-19 prevention, its effectiveness may be reduced in patients with multiple myeloma, likely because of immunosuppression due to the disease process and related therapy. Read more.
A novel high-sensitivity screening approach led to detection of monoclonal gammopathy of undetermined significance at significantly higher rates than conventional methods among people at high risk for multiple myeloma. Read more.
The FDA approved a combination of carfilzomib (Kyprolis, Amgen), a subcutaneous formulation of daratumumab (Darzalex Faspro, Janssen Biotech), and dexamethasone for adults with multiple myeloma who received up to three prior lines of therapy. Read more.
Novel therapies and treatment strategies could help to address the clinical challenges of triple-class refractory multiple myeloma, according to a speaker at Chemotherapy Foundation Symposium. Read more.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Coverage

Read more

Spotlight on multiple myeloma: New drug approvals highlight treatment advances

Related Content